According to Xinhua News Agency, Beijing, May 27th, a brain-computer interface technology development company co-founded by American Silicon Valley entrepreneur Elon Musk announced on the 25th that it has been approved by the US Food and Drug Administration to conduct human trials.
The company called “Neural Connection” tweeted on the social platform that day that it has not yet started clinical trials and has not started recruiting patients who are willing to participate in the trials. The details of the FDA’s approval of NeuroConnect to conduct human trials are unclear.
▲ On September 29, 2017, in Adelaide, Australia, Elon Musk, founder and CEO of SpaceX, gave a keynote speech before the closing ceremony of the 68th International Astronautical Congress. Xinhua News Agency
The “Neural Connection” company hopes that by implanting electrodes, chips and other devices into the human brain, it will establish a communication and control channel connecting the human brain and external devices, that is, a brain-computer interface, so as to directly control external devices or The purpose of external stimuli to regulate brain activity. If successful, the technology could benefit patients with vision or mobility impairments, or some other medical condition.
The brain-computer interface developed by the company “Neural Connection” is a tiny device that can be implanted into the human brain. It has 64 extremely thin wires and 1024 electrodes throughout. There is also an electronic component with a chip in this device, which can wirelessly transmit the brain neural activity captured by the wire to the application program, and the program “decodes” and analyzes the brain’s intentions. The device may be charged wirelessly.
Neural Link has already tested chips from related devices in monkeys. The company was established in 2016 and applied for human trials in 2022, but was not approved by the Food and Drug Administration at that time.
According to the US Consumer News and Business Channel, the development of brain-computer interface technology has a history of several decades. At present, many companies are committed to developing related technologies, but none of them has obtained the approval of the Drug Administration to put the technology into commercial application.
A Swiss research team published an article in the British “Nature” magazine on the 24th to introduce the establishment of a “brain-spinal cord interface” for a paralyzed patient. They implanted electrodes in the patient’s brain and spinal cord, allowing the patient to stand, walk and even climb stairs more autonomously with the help of a walker after more than 10 years of paralysis.
Edited by Chen Yanting Source: Xinhua News Agency
On-duty editor Li Jiamin
Great Wall Motor reported BYD, the response came
Teachers to smear the Resist US Aggression and Aid Korea? Lanzhou University responds
Take you to understand contemporary young people in one breath